Sorrento Therapeutics Inc

+0.06 (+2.26%)
Products, Regulatory

Sorrento Receives Authorization From UK Regulatory Agency To Conduct Phase 2 Trial For Covi-Drops In Outpatient Setting

Published: 06/11/2021 22:54 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Receives Authorization From the Uk Regulatory Agency to Conduct a Phase 2 Clinical Trial for Covi-drops in an Outpatient Setting.
Sorrento Therapeutics Inc - Large Phase 2 Efficacy Trial Cleared to Start in United Kingdom in Newly Diagnosed Sars-cov-2 Infected Patients.
Sorrento Therapeutics- Application Was Submitted As Rolling Application and Mhra Cleared Study in Less Than a Month From Co's First Submission to Mhra.
Sorrento Therapeutics - in Study, There Were No Serious Adverse Effects Or Dose Limiting Toxicities and All Adverse Effects Were Mild in Severity.
Sorrento Therapeutics Inc - Maximum Tolerated Dose Was Not Reached.